Tatva Chintan Pharma Chem Files Compliance Certificate for Q4 FY26
Tatva Chintan Pharma Chem Limited submitted a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate was provided by their Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The information confirms proper processing of dematerialised securities.
This is a standard regulatory filing related to share transfer and dematerialisation, which is a routine process for listed companies. It does not introduce any new material information that would significantly impact the company's operations or stock.
The announcement is a routine compliance filing and does not contain any new financial information or significant business developments that would impact the company's sentiment.
Tatva Chintan Pharma Chem Limited has submitted a compliance certificate for the quarter ended March 31, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was received from MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent.
The certificate confirms that securities received from depository participants for dematerialisation during the quarter were processed and confirmed with the depositories. It also states that the securities listed on the stock exchanges have been duly processed, and certificates received for dematerialisation were cancelled and replaced with the depositories' names in the register of members within the prescribed timelines.
This information will be uploaded on the company's official website, www.tatvachintan.com, for public record. The submission was made on April 6, 2026.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.